(19)
(11) EP 1 906 183 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Mention of the grant of the patent:
13.02.2013 Bulletin 2013/07

(21) Application number: 07007252.5

(22) Date of filing: 05.04.2007
(51) International Patent Classification (IPC): 
G01N 33/68(2006.01)
G06F 19/24(2011.01)
G01N 33/50(2006.01)
G01N 30/02(2006.01)
G01N 1/28(2006.01)

(54)

Method for analysis of metabolite difference between two biological samples using gas chromatography-mass spectrometry

Verfahren zur Analyse von Metabolitunterschieden zwischen zwei biologischen Proben mittels Gaschromatographie-Massenspektrometrie

Procédé et analyse de la différence métabolique entre deux prélèvements biologiques utilisant un spectromètre de masse chromatographique à gaz


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 27.09.2006 KR 20060094002

(43) Date of publication of application:
02.04.2008 Bulletin 2008/14

(73) Proprietor: Korea Institute of Science and Technology
Seoul 136-790 (KR)

(72) Inventors:
  • Jung, Byung Hwa
    Seocho-gu Seoul 137-758 (KR)
  • Chung, Bong Chul
    Namyangju-si Gyeonggi-do 472-709 (KR)

(74) Representative: Ferreccio, Rinaldo 
Botti & Ferrari S.r.l. Via Cappellini, 11
20124 Milano
20124 Milano (IT)


(56) References cited: : 
WO-A-02/057989
   
  • KIM JIN YOUNG ET AL: "Simultaneous determination of carisoprodol and meprobamate in human hair using solid-phase extraction and gas chromatography/mass spectrometry of the trimethylsilyl derivatives." RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2005, vol. 19, no. 21, 2005, pages 3056-3062, XP002465221 New York NY USA ISSN: 0951-4198
  • E.J. CONE ET AL: "Assay for codeine, morphine and ten potential urinary metabolites by gas chromatography--mass fragmentography." JOURNAL OF CHROMATOGRAPHY 8 JUL 1983, vol. 275, no. 2, 8 July 1983 (1983-07-08), pages 307-318, XP002465222 Amsterdam, The Netherlands ISSN: 0021-9673
  • R.J.P. CANNELL: "Follow-up of natural product isolation", METHODS IN BIOTECHNOLOGY, vol. 20, 1 January 2006 (2006-01-01), pages 463-506, Humana Press, Totowa NJ USA
  • R.J.P. CANNELL: "How to approach the isolation of natural products", METHODS IN BIOTECHNOLOGY, vol. 4 , - 1 January 1999 (1999-01-01), pages 1-51, Humana Press, Totowa NJ USA
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

BACKGROUND OF THE INVENTION


Field of the Invention



[0001] The invention relates to a method of extracting all metabolites existing in a biological sample to detect a comprehensive difference between metabolites of a control group and a test group, thereby verifying significance thereof. The biological sample being analyzed by the invention includes all materials existing in an organism, such as blood, blood plasma, serum, urine, feces, cerebrospinal fluid, tissue, hair, serous fluid, gastric juice and the like.

Description of the prior art



[0002] Until now, a research using metabolite is mainly concentrated on a targeted metabolomics research of quantitatively analyzing a reference standard of a specific metabolome in a cell under disease state or gene mutated state and then comparing changes in an amount or concentration of metabolites of a test group and a control group or a ratio of amounts or concentrations of metabolites related to a metabolic pathway, so as to clarify a defect occurring in the metabolic pathway when a disease or gene mutation occurs and to induce a disease diagnosis biomarker using it.

[0003] However, there are various metabolites in the organism and it is very difficult in a test to acquire a reference standard of all the metabolites and to conduct a quantitative analysis of it. Accordingly, it has appeared a global metabolomics research as a non-targeted metabolomics, which is capable of verifying a change of the metabolites in the organism on the whole without the complicated analysis steps.

[0004] Actually, such research has been much conducted for a bacteria or plant in which the number of the metabolites existing in the organism is relatively small [Phytochemistry, 62, 929-937(2002); Phytochemistry, 63, 817-836(2003); Phytochemistry, 63, 887-900(2003); Journal of Integrative Biology, 6, 217-234(2002); Electrophoresis, 23, 1642-1651(2002); Nature Biotechnology, 18, 1157-1161(2000); Anal. Chem., 76, 619-626(2004); Plant Cell, 14, 1437-1440(2002); Advan. Enzyme Regul. 43, 67-76(2003); International Immunopharmacology, 4, 1499-1514(2004)]. However, regarding all the animal samples including human, an extract method and an analysis are complicated, there are differences between the individual organisms and an analysis method which is an indicator does not exist, so that the above research has not been almost applied.

[0005] Document WO 02/057989 discloses a method that apply neural network technology to recognize small metabolic changes in microorganisms, plants or animals to detect changers induced by pesticide (herbicide, insecticide, fungicide) treatment, genetic modification, environmental stress, and other external or internal factors that have influence on metabolite concentrations. The method implements recognition of nuclear magnetic resonance spectra, mass spectra, and/or chromatograms of crude plant extracts and association of such spectra or chromatograms with the treatment of tissue before harvest. The spectra and chromatograms have information of all the metabolites above a concentration threshold contained in the plant tissue extract. The method applies mathematical models to the very complex plant tissue extract and allows the detection of treatments with bioregulators such as pesticides, or genetic modifications such as gene insertions or deletions.

[0006] Document Kim Jin Young et Al.: "Simultaneous determination of carisoprodol and meprobamate in human hair using solid-phase extraction and gas chromatography/mass spectrometry of the trimethylsilyl derivatives." - Rapid Communications in Mass Spectrometry: RCM 2005, vol. 19, no. 21 2005, pages 3056-3062, describes a sensitive and robust GC/MS method for the simultaneous determination of CSP and its active metabolite MPB in human hair. Solid-phase extraction was coupled with TMS derivatization to qualify and quantify CSP and MPB in human hair without significant interferences from matrix components, TMS derivatization with BSTFA/ 1% TMCS at high temperature (120°C) for 30 min allowed improved chromatographic selectively and no tailing peak shapes when compared with previous methods that did not include a derivatization step. This study demonstrated several advantages over previous methods for determination of CSP and MPB, such as effective removal of matrix interferences, high specificity and sensitivity, and better repeatability. The method has been validated and effectively applied to hair samples collected from CSP abusers.

[0007] Document E.J. Cone et Al.: "Assay for codeine, morphine and ten potential urinary metabolites by gas chromatography-mass fragmentography." - Journal of Chromatography 8 July 1983, vol. 275, no. 2, July 1983 (1983-07-08), pages 307-318 describes a mass fragmentography (MF) assay for ten potential, minor urinary metabolites of codeine (C) and morphine (M). Sample were hydrolyzed, extracted, derivatized with Tri-Sil Z and analyzed by methane chemical ionization (CI)-MF. The method is sensitive to ca. 0.01 µg/ml for all compounds with the exception of normorphine (NM) which was difficult to extract with chloroform. The sensitivity of the MF assay for NM was only ca. 0.10 µg/ml. Various solvent system were investigated for optimization of extraction efficiency of all metabolites. A separate method for the extraction of NM is reported which utilizes a solid buffer-solvent combination, i.e., potassium carbonate-isopropanol. This latter method provided the best overall recovery of NM (39.0 ± 3.4%). Gas chromatographic (GC) retention times of C, M and metabolites are reported for three liquid phase (3%) on Gas-Chrom Q (100-120 mesh). Resolution of metabolites (as trisilyl derivatives) was best on Silar-5CP and this phase was used in metabolic studies of C and M. GC resolution was not complete for all compound; however, selection of specific ions for monitoring by MF provided the required specificity for all compounds except the 6α- and 6β-hydroxy isomers. CI spectra for all metabolite are reported. The MF assay was used for urinary analysis of samples from guinea pigs that received singles doses of C (15 mg/kg) or M (8 mg/kg). Following C administration 6α- and 6β-hydrocodol, 6α,β-hydromorphol (undifferentiated) HM and M were measured. Following M administration only 6α,β-hydromorphol was found. The amount of total metabolite as percent dose for each component was calculated as < 1%.

[0008] Document R.J.P. Cannel: "How to approach the isolation the isolation of natural products" Method in Biotechnology, vol. 4, - 1 January 1999 (1999-01-01), pages 1-51, Humana Press, Totowa NJ, USA, discloses a general isolation method of compounds, metabolites or molecules for extraction, purification, fractionation, assay and/or quantification, in which the targets of the isolation are all of the metabolites produced by one natural product source. In particular, this document discloses that using a mobile phase gradient of wide ranging polarity and/or different pH values should serve to separate the mixture and elute all the components, and that the method separates one sample into several fractions, then it sets each fraction at different pH values. Moreover, this document D4 discloses an equation, a resolution and/or a method of identity when several types of peaks appear on chromatogram.

[0009] Document R.J.P. Cannel: "Follow-up of natural product isolation" Methods in Biotechnology, vol. 20, 1 January 2006 (2006-01-01) pages 463-506, Humana Press, Totowa NJ, USA discloses a general isolation method of natural products.

[0010] Therefore, it is seriously needed to standardize a method of extracting a biological sample and to develop a method of connecting a device analysis and statistics enabling a metabolite profiling of a test group and a control group, which is obtained by a device analysis chromatogram, to be statistically analyzed.

SUMMARY OF THE INVENTION



[0011] In order to solve the above problem, an object of the invention is to provide a method for defining and using a standard extraction method so as to extract all metabolites from a biological sample, obtaining a chromatogram with a chromatography analysis device, digitizing the chromatogram so that it can be statistically processed, and detecting a significant difference between a control group and a test group with a principle component analysis (PCA) and a discriminant analysis (DA).

[0012] In order to achieve the above object, there is provided a method for detecting differences of concentrations or quantities between metabolites of two biological samples, according to appended claim 1.

BRIEF DESCRIPTION OF THE DRAWINGS



[0013] The above and other objects, features and advantages of the present invention will be more apparent from the following detailed description taken in conjunction with the accompanying drawings, in which:

FIG. 1 is a view comparing chromatogram results so as to compare the effects of an acid hydrolysis and an enzyme hydrolysis in a step of obtaining a fraction 3;

FIG. 2 shows results of a principal component analysis and a discriminant analysis, which are obtained by analyzing a fraction (fraction 1) acquired after extracting a urine sample with a solid phase extraction method;

FIG. 3 shows results of a principal component analysis and a discriminant analysis, which are obtained by analyzing a fraction (fraction 2) acquired with a liquid-liquid extraction method at pH 5.2 after extracting a urine sample with a solid phase extraction method;

FIG. 4 shows results of a principal component analysis and a discriminant analysis, which are obtained by analyzing a fraction (fraction 3) acquired with an organic solvent extraction after hydrolyzing a water layer remained after obtaining the fraction 2; and

FIG. 5 shows results of a principal component analysis and a discriminant analysis, which are obtained by analyzing a fraction (fraction 4) acquired with an organic solvent extraction after adjusting the fraction 3 to be pH 13 using K2CO3.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS



[0014] Hereinafter, a preferred embodiment of the present invention will be described with reference to the accompanying drawings.

[0015] First, a standard extraction method of a sample according to the invention is as follows. A biological sample is extracted with a solid phase extraction method (fraction 1), the remaining solution is again extracted with a liquid-liquid extraction method (fraction 2), a remaining water layer is added with enzyme to hydrolyze the conjugate existing in the biological sample and then the resulting solution is extracted with a liquid-liquid extraction method under weak acid condition (fraction 3) and it is extracted with a liquid-liquid extraction method under base condition (fraction 4).

[0016] The extracted fractions 1 to 4 are evaporized and dried to make derivatives thereof which are then analyzed with a gas chromatography-mass spectrometry. The resulting values are analyzed with a principle component analysis (PCA) and a discriminant analysis (DA), thereby verifying a difference between a control group and a test group.

[0017] The principle component analysis is a statistical technique for finding out a new principle component, which is expressed with a linear connection of variables, for the purpose of the summing-up of the materials and an easy interpretation. In other words, it is an analysis method capable of providing a means for an analysis in future. The discriminant analysis is a statistical technique of using several variable materials obtained for two or more groups to deduce a linear connection of variables exhibiting characteristics of each group, analyzing whether there is a characteristic difference, which is statistically significant, between the respective groups, using the linear connection, and expecting what group a specific observation value belongs to.

[0018] Hereinafter, the invention will be more specifically described with reference to following embodiments. However, it should be noted that they are provided to illustrate the invention, not to limit it.

<embodiment 1: extracting a metabolite from a biological sample with a standard extraction method and analyzing it with a chromatography analysis device>


1.1 obtaining the fraction 1



[0019] Strata X® (Phenomenex, Torrance, Canada; styrene-divinyl benzene polymer having a surface specially treated for keeping an analysis material from being discharged from a cartridge using a π-π interaction) cartridge was mounted to a solid phase extraction vacuum manifold, which was added with methanol 1 mℓ to activate it and then washed with water 1 mℓ, thereby carrying out a pre-treatment. Urine 1 mℓ, which was obtained from 10 prostatic hypertrophy patients (average age: 60±5 years) and 10 normal males (average age: 58±7 years) whose age is matched with that of the patients, was loaded to the cartridge, water 1 mℓ was again added to wash it and then methanol 4 mℓ was made to flow, thereby discharging an analysis-object material. Among them, only 0.3 mℓ was taken and evaporated and dried with a vacuum rotary evaporator and the remnant thereof was added with a derivatizing reagent 50 µℓ having mixed MSTFA (N-Methyl-N-(trimethylsilyl) trifluoroacetamide), NH4I (ammonium iodide) and dithiolerythritol in a ratio of 100:4:5 (v/v), which was then subject to a reaction at 60°C for 15 minutes for the purpose of derivatization.

1-2. obtaining the fraction 2



[0020] The effluent remaining in the above 1-1 was evaporated and dried with the vacuum rotary evaporator and the remnant thereof was added with an acetic acid buffer solution (pH 5.2) 1 mℓ and then diethylether 5 mℓ, which was then shaken for 5 minutes, thereby carrying out a liquid-liquid extraction method. The extracted diethylether layer was centrifugally separated at 2500 rpm for 5 minutes, which was then again evaporated and dried with the vacuum rotary evaporator. Then, the remnant thereof was added with a derivatizing reagent 50 µℓ having mixed MSTFA (N-Methyl-N-(trimethylsilyl) trifluoroacetamide), NH4I (ammonium iodide) and dithiolerythritol in a ratio of 100:4:5 (v/v), which was then subject to a reaction at 60°C for 15 minutes for the purpose of derivatization.

1-3. obtaining the fraction 3



[0021] In order to hydrolyze the glucuronide conjugate and sulfate conjugate, which most exist in the organism, thereby obtaining a conjugate form of metabolites in a free form, the water layer, which remained after separating the diethylether in the above 1-2, was added with β-glucuronidase/arylsulfatase (Helix pomatia, Roche, Mannheim, Germany) 100 µℓ, which was then hydrolyzed at 55°C for 3 hours.

[0022] After the hydrolysis, the solution was added with diethylether 5 mℓ and then shaken for 5 minutes, thereby conducting the liquid-liquid extraction method again. The extracted diethylether layer was centrifugally separated at 2500 rpm for 5 minutes, which solution was evaporated and dried with the vacuum rotary evaporator. Then, the remnant thereof was added with a derivatizing reagent 50 µℓ having mixed MSTFA (N-Methyl-N-(trimethylsilyl) trifluoroacetamide), NH4I (ammonium iodide) and dithiolerythritol in a ratio of 100:4:5 (v/v), which was then subject to a reaction at 60°C for 15 minutes for the purpose of derivatization.

[0023] There are acid hydrolysis and enzyme hydrolysis as a method for obtaining the conjugate form of metabolite, which exists in the urine sample, in a free form. A test was conducted to confirm which method was effective. For the enzyme hydrolysis, the method described in the above 1-3 was used. For the acid hydrolysis, the water layer, which remained after obtaining the fraction 2 in the above 1-2, was added with 0.1N hydrochloric acid 1 mℓ, which was then subject to the hydrolysis at 80°C for 1 hour. Then, under cooled at the room temperature, pH thereof was adjusted to be 5.2 with 0.1N NaOH. According to a chromatogram result of the two fractions, approximately same chromatogram tendencies were exhibited as shown in Fig. 1. However, since the very small amount of metabolites is apt to be degenerated under acid condition, the enzyme hydrolysis was used finally.

1-4. obtaining the fraction 4



[0024] K2CO3 100 mg was again added to the remaining water layer to make an alkaline condition of pH 13, which was then added with diethylether 5 mℓ and shaken for 5 minutes, thereby conducting the liquid-liquid extraction method. The extracted diethylether layer was centrifugally separated at 2500 rpm for 5 minutes, which solution was evaporated and dried with the vacuum rotary evaporator. Then, the remnant thereof was added with a derivatizing reagent 50 µℓ having mixed MSTFA (N-Methyl-N-(trimethylsilyl) trifluoroacetamide), NH4I (ammonium iodide) and dithiolerythritol in a ratio of 100:4:5 (v/v), which was then subject to a reaction at 60°C for 15 minutes for the purpose of derivatization.

1.5 analyzing the obtained fractions with a chromatography analysis device



[0025] In order to analyze the metabolites, it was used a 6890 Plus gas chromatograph (Agilent Co., Tokyo, Japan) having a 5973 mass spectrometry (Agilent Co.) mounted thereto and a ultra 1 column (Agilent Co.) having a length of 17m and an inner diameter of 0.2 mm and comprising a film having a thickness of 0.33 µm and coated in the column. In the analysis, an oven temperature condition of the gas chromatograph was as follows: the initial temperature was adjusted to be 100°C and the temperature was increased to 300°C at a rate of 10°C per minute. Helium was used as an analyzer carrier gas and a flow rate thereof was 1 mℓ/minute. An introducing part of the analyzer was 250°C, a temperature of the detector was 280°C and a split ratio was 10:1 when introducing the sample. All the samples were analyzed in a scan mode in the mass spectrometry.

<embodiment 2: converting the analysis result of the chromatography into numerical values which can be statistically processed>



[0026] The areas or heights of the peaks occurring in the chromatograms of the respective fractions represent the concentration or the quantity of the metabolites in the sample. Since the peaks are not always generated as a predetermined number at a fixed time, they cannot be applied to the statistical process in which the number of variables should be constant.

[0027] In order to solve the problem, the total analysis time of 30 minutes were divided at an interval of 1 minute so that the time interval was same, and one of the peaks, which occurred for 1 minute, having the largest area was determined as a representative value, thereby conducting a statistical process.

<embodiment 3: statistically verifying a difference between two biological samples using the converted numerical values>



[0028] As the statistical process method for the global metabolomics, the principal component analysis and the discriminant analysis were used. A leave-one out method (when the number of samples is assumed to be 100, a control group is made for the 99 samples and it is determined whether the remaining one sample belongs to a normal group or a disease group) was adopted for the discriminant analysis. It was measured an accuracy in discriminating the unknown sample as a normal person or a prostatic hypertrophy patients with the results obtained from the discriminant analysis.

[0029] As a result, clustering patterns discriminating between the group of the normal people and the group of patients were exhibited in the principal component analysis of the fraction 2 (fraction obtained by the liquid-liquid extraction at pH 5.2 after the solid phase extraction, Fig. 3) and the fraction 3 (fraction obtained by the liquid-liquid extraction at pH 5.2 after the hydrolysis, Fig. 4). In particular, according to the result of discriminant analysis, when the statistical analysis was conducted with the fraction 2, the prostatic hypertrophy patient and the normal person were discriminated in the high accuracy (77% or more). Therefore, it was judged as follows: when the sample is extracted as a method for obtaining the fraction 2 (liquid-liquid extraction at pH 5.2 after the solid phase extraction), the metabolic change of the prostatic hypertrophy can be detected best, so that the metabolic difference between the prostatic hypertrophy patient and the normal person can be discriminated in the high accuracy. In the mean time, the difference of the clustering patterns was remarkably decreased in the principal component analysis of the fraction 1 (fraction analyzed immediately after the solid phase extraction, Fig. 2) and the fraction 4 (fraction analyzed after the liquid-liquid extraction at pH 13 after the hydrolysis, Fig. 5) and the diagnosis accuracy of the discriminant analysis was not good (i.e., 57% or less).

[0030] As described above, according to the invention, the whole metabolites included in the biological sample are effectively extracted and analyzed with a high-sensitive analysis device, so that the metabolite profile can be effectively measured. With the result, the statistical verification is conducted. Accordingly, when a disease appears or when administrating an extrinsic material, it is possible to measure the change of the metabolites in the organism, effectively and appropriately.


Claims

1. A method for detecting differences of concentrations or quantities between metabolites of two biological samples, the method comprising sequentially performing the following steps:

(i) extracting fraction 1 using a Strata XR solid phase extraction method, wherein the solid phase is pretreated with methanol to activate it and wherein the extraction is performed by first adsorbing metabolites and subsequently discharging them with methanol and finally derivatizing part of said discharged fraction 1 metabolites by reacting a portion of said fraction 1 with a mixture of MSTFA (N-Methyl-N-(trimethylsilyl) trifluoroacetamide), NH4I (ammonium iodide) and dithiolerythritol in a ratio of 100:4:5 (vol/vol/vol) for 15 minutes at 60°C;

(ii) separating fraction 2 from the remaining underivatized fraction 1 using a liquid-liquid extraction method after buffering said fraction 1 at pH 5 to pH 5.5, wherein the liquid-liquid extraction is performed by shaking said fraction 1 with a mixture of acetic acid buffer and diethylether in a ratio of 1:5 vol/vol for 5 minutes and finally derivatizing part of said extracted fraction 2 metabolites by reacting a portion thereof with a mixture of MSTFA, NH4I and dithiolerythritol in a ratio of 100:4:5 (vol/vol/vol) for 15 minutes at 60°C;

(iii) hydrolyzing the remaining underivatized liquid phase left over after separating said fraction 2 at 55°C for 3 hours using beta-glucuronidase/arylsulfatase (Helix pomatia, RocheR, Mannheim) 100 µℓ, and separating fraction 3 from the hydrolyzed left over liquid phase using a liquid-liquid extraction method by shaking said left over for 5 minutes with diethylether and finally derivatizing part of said fraction 3 metabolites by reacting a portion thereof with a mixture of MSTFA, NH4I and dithiolerythritol in a ratio of 100:4:5 (vol/vol/vol) for 15 minutes at 60°C; and

(iv) separating fraction 4 from the remaining underivatized liquid phase left after separating said fraction 3, by using a liquid-liquid extraction method by shaking said left over liquid phase for 5 minutes with diethylether after buffering said left over liquid phase at pH 13-13.5 with K2CO3 and finally derivatizing part of said extracted fraction 4 metabolites by reacting a portion thereof with a mixture of MSTFA, NH4I and dithiolerythritol in a ratio of 100:4:5 (vol/vol/vol) for 15 minutes at 60°C; and

(v) performing chromatography on each of said derivatized fractions 1 to 4 with a gas chromatography-mass spectrometry analysis device; converting a result of said chromatography into numerical values by dividing a total chromatography performing time at 1 minute intervals and determining the highest value of areas of chromatogram peaks or the highest value of heights of chromatogram peaks exhibited during 1 minute as a representative value of each 1 minute period and analyzing the numerical values from the first biological sample group and the numerical values from the second biological sample group with principle component analysis and discriminant analysis, and thus determining whether there is a statistically significant difference between the numerical values of said two sample groups.


 


Ansprüche

1. Verfahren zum Detektieren von Konzentrations- oder -Mengenunterschieden zwischen Metaboliten von zwei biologischen Proben, wobei das Verfahren das aufeinanderfolgende Ausführen folgender Schritte umfasst:

(i) Extrahieren von Fraktion 1 unter Verwendung eines Strata XR Festphasenextraktionsverfahrens, wobei die feste Phase mit Methanol vorbehandelt ist, um sie zu aktivieren und, wobei die Extraktion durch zuerst Adsorbieren der Metabolite und anschließend durch ihr Ablösen mit Methanol und schließlich durch Derivatisieren eines Teils der abgelösten Fraktion 1-Metabolite durch Reagierenlassen eines Teils von Fraktion 1 mit einer Mischung aus MSTFA (N-Methyl-N-(trimethylsilyl)trifluoracetamid), NH4I (Ammonniumiodid) und Dithioerythritol in einem Verhältnis von 100:4:5 (Vol/Vol/Vol) für 15 min bei 60°C ausgeführt wird;

(ii) Abtrennen von Fraktion 2 aus der verbleibenden nicht-derivatisierten Fraktion 1 unter Verwendung eines Flüssig-Flüssig-Extraktionsverfahrens nach Puffern von Fraktion 1 bei pH 5 bis pH 5,5; wobei die Flüssig-Flüssig-Extraktion durch Schütteln von Fraktion 1 mit einer Mischung aus Essigsäurepuffer und Diethylether in einem Verhältnis von 1:5 Vol/Vol für 5 Minuten und schließlich durch Derivatisieren eines Teils der extrahierten Fraktion 2-Metabolite durch Reagierenlassen eines Teils davon mit einer Mischung aus MSTFA, NH4I und Dithioerythritol in einem Verhältnis von 100:4:5 (Vol/Vol/Vol) für 15 Minuten bei 60°C ausgeführt wird;

(iii) Hydrolysieren der verbleibenden nicht-derivatisierten flüssigen Phase, die nach Abtrennen von Fraktion 2 bei 55°C für 3 Stunden unter Verwendung von 100 µl Beta-Glucuronidase/Arylsulfatase (Helix pomatia, RocheR, Mannheim) übrigbleibt, und Abtrennen von Fraktion 3 aus der hydrolysierten übriggebliebenen flüssigen Phase unter Verwendung eines Flüssig-Flüssig-Extraktionsverfahrens durch Schütteln der übriggebliebenen Phase für 5 Minuten mit Diethylether und schließlich Derivatisieren eines Teils der Fraktion 3-Metabolite durch Reagierenlassen eines Teils davon mit einer Mischung aus MSTFA, NH4I und Dithioerythritol in einem Verhältnis von 100:4:5 (Vol/Vol/Vol) für 15 Minuten bei 60°C; und

(iv) Abtrennen von Fraktion 4 aus der verbleibenden nicht-derivatisierten flüssigen Phase, die nach Abtrennen von Fraktion 3 übrigbleibt, unter Verwendung eines Flüssig-Flüssig-Extraktionsverfahrens durch Schütteln der übriggebliebenen flüssigen Phase für 5 Minuten mit Diethylether nach Puffern der übriggebliebenen flüssigen Phase bei pH 13-13,5 mit K2CO3 und schließlich Derivatisieren eines Teils der extrahierten Fraktion 4-Metabolite durch Reagierenlassen eines Teils davon mit einer Mischung aus MSTFA, NH4I und Dithioerythritol in einem Verhältnis von 100:4:5 (Vol/Vol/Vol) für 15 Minuten bei 60°C; und

(v) Ausführen von Chromatographie an jeder der derivatisierten Fraktionen 1 bis 4 mit einer Gaschromatographie-Massenspektrometrie-Analyseeinrichtung; Umrechnen eines Ergebnisses dieser Chromatographie in Zahlenwerte durch Teilen einer Chromatographie-Gesamtausführzeit in 1 Minute-Intervallen und Bestimmen des höchsten Werts der Chromatographie-Peakflächen oder des höchsten Werts der Chromatographie-Peakhöhen, die sich während 1 Minute als ein charakteristischer Wert für jeden der 1 Minute-Zeiträume ausbilden und Analysieren der Zahlenwerte aus der ersten biologischen Probengruppe und der Zahlenwerte aus der zweiten biologischen Probengruppe mit Hauptkomponentenanalyse und Diskriminanzanalyse, und dadurch Bestimmen, ob zwischen den Zahlenwerten beider Probengruppen ein statistisch signifikanter Unterschied besteht.


 


Revendications

1. Procédé de détection de différences de concentrations ou de quantités entre des métabolites de deux échantillons biologiques, le procédé comprenant l'exécution de manière séquentielle des étapes suivantes :

(i) une extraction d'une fraction 1 au moyen d'un procédé d'extraction en phase solide Strata XR, dans lequel la phase solide est prétraitée avec du méthanol afin de l'activer et dans lequel l'extraction est effectuée tout d'abord en adsorbant des métabolites et en les libérant ensuite grâce à du méthanol et enfin en formant un dérivé d'une partie desdits métabolites de fraction 1 libérés par réaction d'une partie de ladite fraction 1 avec un mélange de MSTSA (N-méthyl-N-(triméthylsilyle)-trifluoroacétamide), de NH4I (iodure d'ammonium) et de dithiolérythritol selon un rapport de 100:4:5 (vol/vol/vol) pendant 15 minutes à 60 °C ;

(ii) une séparation d'une fraction 2 à partir de la fraction 1 non dérivée restante au moyen d'un procédé d'extraction liquide-liquide après avoir tamponné ladite fraction 1 à un pH compris entre 5 et 5,5, où l'extraction liquide-liquide est effectuée en agitant ladite fraction 1 avec un mélange de tampon d'acide acétique et de diéthyléther selon un rapport de 1:5 vol/vol pendant 5 minutes et enfin en formant un dérivé d'une partie desdits métabolites de fraction 2 extraits par réaction d'une partie de ceux-ci avec un mélange de MSTSA, de NH4I et de dithiolérythritol selon un rapport de 100:4:5 (vol/vol/vol) pendant 15 minutes à 60 °C ;

(iii) une hydrolysation de la phase liquide non dérivée restant après séparation de ladite fraction 2 à 55°C pendant 3 heures en utilisant 100 µl de bêta-glucuronidase/arylsulfatase (Helix pomatia RocheR, Mannheim), et une séparation d'une fraction 3 à partir de la phase liquide restante hydrolysée au moyen d'un procédé d'extraction liquide-liquide en agitant ladite phase restante pendant 5 minutes avec du diéthyléther et enfin en formant un dérivé d'une partie desdits métabolites de fraction 3 par réaction d'une partie de ceux-ci avec un mélange de MSTSA, de NH4I et de dithiolérythritol selon un rapport de 100:4:5 (vol/vol/vol) pendant 15 minutes à 60 °C ; et

(iv) une séparation d'une fraction 4 à partir de la phase liquide non dérivée restant après séparation de ladite fraction 3, au moyen d'une méthode d'extraction liquide-liquide en agitant ladite phase liquide restante pendant 5 minutes avec du diéthyléther après avoir tamponné ladite phase liquide restante à un pH compris entre 13 et 13,5 avec du K2CO3 et enfin en formant un dérivé d'une partie desdits métabolites de fraction 4 extraits par réaction d'une partie de ceux-ci avec un mélange de MSTSA, de NH4I et de dithiolérythritol selon un rapport de 100:4:5 (vol/vol/vol) pendant 15 minutes à 60 °C ; et

(v) une réalisation d'une chromatographie sur chacune desdites fractions dérivées 1 à 4 avec un dispositif d'analyse par chromatographie gazeuse et spectrométrie de masse ; une conversion d'un résultat de ladite chromatographie en valeurs numériques par division d'une durée de réalisation de chromatographie totale en intervalles de 1 minute et par détermination de la valeur la plus élevée des surfaces des pics de chromatogramme ou de la valeur la plus élevée des hauteurs des pics de chromatogramme apparaissant au cours de 1 minute en tant que valeur représentative de chaque période de 1 minute et une analyse des valeurs numériques émanant du premier groupe d'échantillons biologiques et des valeurs numériques émanant du deuxième groupe d'échantillons biologiques par analyse de constituant principal et analyse discriminante, et de cette manière une détermination du fait qu'il existe une différence statistiquement significative entre les valeurs numériques desdits deux groupes d'échantillons.


 




Drawing




















Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description